Published in

American Society for Clinical Investigation, Journal of Clinical Investigation, 4(118), p. 1350-1353

DOI: 10.1172/jci35326

Links

Tools

Export citation

Search in Google Scholar

HOXB4 and retroviral vectors: Adding fuel to the fire

Journal article published in 2008 by Andre Larochelle ORCID, Cynthia E. Dunbar
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The transcription factor homeobox B4 (HOXB4) is a promising agent capable of providing a growth advantage to genetically modified hematopoietic stem and progenitor cells (HSPCs). In this issue of the JCI, Zhang and colleagues overexpressed HOXB4 in HSPCs from large animals using retroviral vectors (see the related article beginning on page 1502). Two years after transplantation, most animals developed leukemia, a consequence of combined HOXB4 and deregulated protooncogene expression. These results highlight the risks of combining integrating vectors and growth-promoting genes for clinical applications.